Condensed Consolidated Statements of Changes in Equity (Statement) - USD ($)		Total		Conversion Of Convertible Common Units	Common Units	Common Units Conversion Of Convertible Common Units		Common Stock	Common Stock Conversion Of Convertible Common Units	Additional Paid-in Capital	Additional Paid-in Capital Conversion Of Convertible Common Units	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Non-controlling Interests	Non-controlling Interests Conversion Of Convertible Common Units
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023		$ 7,302,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(2,285,000)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2024		5,017,000
Common units balance, beginning of period (in shares) at Dec. 31, 2023	[1]				484,922,828
Balance, beginning of period at Dec. 31, 2023		1,075,014,000			$ 496,882,000			$ 0		$ 0		$ 18,561,000	$ 155,453,000	$ 404,118,000
Balance, beginning of period (in shares) at Dec. 31, 2023								0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health, Inc.		27,047,000											27,047,000
Net income attributable to noncontrolling interests		21,089,000												21,089,000
Other comprehensive income (loss)		703,000										703,000
Distributions to noncontrolling interests		(14,256,000)												(14,256,000)
Vesting of Class C Units (in shares)	[1]				464,853
Vesting of Class C Units		512,000			$ 512,000
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs (in shares)	[1]				464,853
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs		512,000			$ 512,000
Common units balance, ending of period (in shares) at Mar. 31, 2024	[1]				485,387,681
Balance, ending of period at Mar. 31, 2024		1,110,109,000			$ 497,394,000			$ 0		0		19,264,000	182,500,000	410,951,000
Balance, ending of period (in shares) at Mar. 31, 2024								0
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023		7,302,000
Redeemable noncontrolling interests, ending balance at Sep. 30, 2024		2,391,000
Common units balance, beginning of period (in shares) at Dec. 31, 2023	[1]				484,922,828
Balance, beginning of period at Dec. 31, 2023		1,075,014,000			$ 496,882,000			$ 0		0		18,561,000	155,453,000	404,118,000
Balance, beginning of period (in shares) at Dec. 31, 2023								0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health, Inc.		96,139,000
Other comprehensive income (loss)		(9,075,000)
Common units balance, ending of period (in shares) at Sep. 30, 2024	[1]				0
Balance, ending of period at Sep. 30, 2024		1,384,478,000			$ 0			$ 1,428,000		743,364,000		9,486,000	251,592,000	378,608,000
Balance, ending of period (in shares) at Sep. 30, 2024								142,735,842
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2024		5,017,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,349,000)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2024		3,668,000
Common units balance, beginning of period (in shares) at Mar. 31, 2024	[1]				485,387,681
Balance, beginning of period at Mar. 31, 2024		1,110,109,000			$ 497,394,000			$ 0		0		19,264,000	182,500,000	410,951,000
Balance, beginning of period (in shares) at Mar. 31, 2024								0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health, Inc.		42,770,000											42,770,000
Net income attributable to noncontrolling interests		25,540,000												25,540,000
Other comprehensive income (loss)		(2,255,000)										(2,255,000)
Distributions to noncontrolling interests		(17,401,000)												(17,401,000)
Vesting of Class C Units (in shares)	[1]				522,002
Vesting of Class C Units		226,000			$ 226,000
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs (in shares)	[1]				522,002
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs		226,000			$ 226,000
Common units balance, ending of period (in shares) at Jun. 30, 2024	[1]				485,909,683
Balance, ending of period at Jun. 30, 2024		1,158,989,000			$ 497,620,000			$ 0		0		17,009,000	225,270,000	419,090,000
Balance, ending of period (in shares) at Jun. 30, 2024								0
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,277,000)
Redeemable noncontrolling interests, ending balance at Sep. 30, 2024		2,391,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health, Inc.		26,322,000											26,322,000
Net income attributable to noncontrolling interests		20,960,000												20,960,000
Other comprehensive income (loss)		(7,523,000)										(7,523,000)
Distributions to noncontrolling interests		(21,481,000)												(21,481,000)
Vesting of Class C Units (in shares)								13,800,000
Vesting of Class C Units		199,122,000						$ 138,000		198,984,000
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs (in shares)								13,800,000
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs		199,122,000						$ 138,000		198,984,000
Conversion of member units to common stock (in shares)						(485,909,683)	[1]		128,963,328
Conversion of member units to common stock				$ 0		$ (497,620,000)			$ 1,290,000		$ 536,291,000				$ (39,961,000)
Vesting of restricted stock unit awards										9,441
Tax withholding on vesting of restricted stock unit awards (in shares)								(2,396)
Tax withholding on vesting of restricted stock unit awards		(46,000)								(46,000)
Forfeitures of restricted stock awards (in shares)								(34,531)
Common units balance, ending of period (in shares) at Sep. 30, 2024	[1]				0
Balance, ending of period at Sep. 30, 2024		1,384,478,000			$ 0			$ 1,428,000		743,364,000		9,486,000	251,592,000	378,608,000
Balance, ending of period (in shares) at Sep. 30, 2024								142,735,842
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024		1,158,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,350,000)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2025		(192,000)
Balance, beginning of period at Dec. 31, 2024		$ 1,521,199,000	[2]					$ 1,428,000		754,415,000		9,737,000	365,796,000	389,823,000
Balance, beginning of period (in shares) at Dec. 31, 2024		142,747,818						142,747,818
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health, Inc.		$ 41,383,000											41,383,000
Net income attributable to noncontrolling interests		18,932,000												18,932,000
Other comprehensive income (loss)		(5,809,000)										(5,809,000)
Distributions to noncontrolling interests		(19,239,000)												(19,239,000)
Vesting of restricted stock unit awards (in shares)								289,946
Vesting of restricted stock unit awards		(1,061,000)						$ 2,000		(1,063,000)
Equity-based compensation		9,263,000								9,263,000
Balance, ending of period at Mar. 31, 2025		1,564,668,000						$ 1,430,000		762,615,000		3,928,000	407,179,000	389,516,000
Balance, ending of period (in shares) at Mar. 31, 2025								143,037,764
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024		1,158,000
Redeemable noncontrolling interests, ending balance at Sep. 30, 2025		(1,489,000)
Balance, beginning of period at Dec. 31, 2024		$ 1,521,199,000	[2]					$ 1,428,000		754,415,000		9,737,000	365,796,000	389,823,000
Balance, beginning of period (in shares) at Dec. 31, 2024		142,747,818						142,747,818
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health, Inc.		$ 90,855,000
Other comprehensive income (loss)		(12,371,000)
Balance, ending of period at Sep. 30, 2025		$ 1,633,336,000	[2]					$ 1,432,000		782,765,000		(2,634,000)	456,651,000	395,122,000
Balance, ending of period (in shares) at Sep. 30, 2025		143,169,831						143,169,831
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2025		$ (192,000)
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,559,000)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2025		(1,751,000)
Balance, beginning of period at Mar. 31, 2025		1,564,668,000						$ 1,430,000		762,615,000		3,928,000	407,179,000	389,516,000
Balance, beginning of period (in shares) at Mar. 31, 2025								143,037,764
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health, Inc.		72,950,000											72,950,000
Net income attributable to noncontrolling interests		24,310,000												24,310,000
Other comprehensive income (loss)		(4,324,000)										(4,324,000)
Distributions to noncontrolling interests		(20,286,000)												(20,286,000)
Vesting of Class C Units (in shares)								7,553
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs (in shares)								7,553
Vesting of restricted stock unit awards (in shares)								66,306
Vesting of restricted stock unit awards		(438,000)						$ 1,000		(439,000)
Forfeitures of restricted stock awards (in shares)								(13,117)
Equity-based compensation		11,246,000								11,246,000
Balance, ending of period at Jun. 30, 2025		1,648,126,000						$ 1,431,000		773,422,000		(396,000)	480,129,000	393,540,000
Balance, ending of period (in shares) at Jun. 30, 2025								143,098,506
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		262,000
Redeemable noncontrolling interests, ending balance at Sep. 30, 2025		(1,489,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health, Inc.		(23,478,000)											(23,478,000)
Net income attributable to noncontrolling interests		24,423,000												24,423,000
Other comprehensive income (loss)		(2,238,000)										(2,238,000)
Vesting of restricted stock unit awards		(330,000)								(331,000)
Equity-based compensation		8,135,000								8,135,000
Balance, ending of period at Sep. 30, 2025		$ 1,633,336,000	[2]					$ 1,432,000		$ 782,765,000		$ (2,634,000)	$ 456,651,000	$ 395,122,000
Balance, ending of period (in shares) at Sep. 30, 2025		143,169,831						143,169,831

[1] See Note 1, Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion, for further discussion.

[2] As of September 30, 2025 and December 31, 2024, the unaudited condensed consolidated balance sheets included total liabilities of consolidated variable interest entities of $309.0 million and $306.4 million, respectively. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion.